Absci Corporation (Nasdaq: ABSI), a generative AI drug creation
company, and Almirall S.A. (BME: ALM), a global biopharmaceutical
company focused on medical dermatology, today announced a drug
discovery partnership aimed to develop and commercialize
AI-designed therapeutics to fight chronic and debilitating
dermatological diseases. The partnership combines Absci’s
Integrated Drug Creation™ platform with Almirall’s dermatological
expertise with the goal of delivering life-changing medicines to
patients, marking another step forward in AI drug creation.
The partnership represents Almirall’s first de
novo AI drug collaboration, and it comes only months after Absci
announced it could design and validate de novo therapeutic
antibodies using its ‘zero-shot’ generative AI. Under the terms of
the partnership, Absci will apply its de novo generative AI
technology to create and commercialize therapeutic candidates for
two dermatological targets. In addition to product royalties, Absci
is eligible to receive up to approximately $650 million in upfront
fees, R&D, and post-approval milestone payments across the two
programs if all milestones are successfully completed.
“Almirall chose Absci because their de novo
platform brings truly novel innovation in solving the industry’s
most challenging targets facing high unmet medical need,” said
Almirall Executive VP of R&D and CSO Dr. Karl
Ziegelbauer. “Our partnership underlines Almirall’s
commitment to target innovative approaches to help patients
suffering from severe skin diseases to achieve their dream of
leading a healthy life.”
“Our partnership with Almirall marks an
important leap forward for dermatologic drug development and is
poised to transform the lives of millions managing skin
conditions,” said Absci Founder and CEO Sean
McClain. “We believe the collaboration will generate
tremendous scientific and technical insights for using AI drug
creation to treat chronic inflammatory diseases more broadly.
Working with a global leader and visionary in skin disease on this
ambitious project will accelerate our journey in creating better
biologics for a broad range of diseases affecting millions
daily.”
About Absci
Absci is a generative AI drug creation company
that combines AI with scalable wet lab technologies to create
better biologics for patients, faster. Our Integrated Drug
Creation™ platform unlocks the potential to accelerate time to
clinic and increase the probability of success by simultaneously
optimizing multiple drug characteristics important to both
development and therapeutic benefit. With the data to learn, the AI
to create, and the wet lab to validate, Absci can screen billions
of cells per week, allowing it to go from AI-designed antibodies to
wet lab-validated candidates in as little as six weeks. Absci’s
vision is to deliver breakthrough therapeutics at the click of a
button, for everyone. Absci's headquarters is in Vancouver, WA, its
AI Research Lab is in New York City, and its Innovation Center is
in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn
(@absci), Twitter (@Abscibio), and YouTube.
About Almirall
Almirall is a global biopharmaceutical company
focused on medical dermatology. We collaborate with scientists and
healthcare professionals to address patients' needs through science
to improve their lives. Our Noble Purpose is at the core of our
work: "Transform the patients' world by helping them realize their
hopes and dreams for a healthy life". We invest in differentiated
and ground-breaking medical dermatology products to bring our
innovative solutions to patients in need.
The company, founded in 1944 and headquartered
in Barcelona, is publicly traded on the Spanish Stock Exchange
(ticker: ALM). Throughout its 79-year history, Almirall has focused
intensely on patients' needs. Almirall has a direct presence in 21
countries and strategic agreements in over 70, with about 1,800
employees. Total revenue in 2022 was €878.5 MM.
For more information, please visit
almirall.com
Availability of Other Information about
Absci
Investors and others should note that we
routinely communicate with investors and the public using our
website (www.absci.com) and our investor relations website
(investors.absci.com), including without limitation, through the
posting of investor presentations, SEC filings, press releases,
public conference calls and webcasts on these websites, as well as
on Twitter, LinkedIn and YouTube. The information that we post on
these websites and social media outlets could be deemed to be
material information. As a result, investors, the media, and others
interested in Absci are encouraged to review this information on a
regular basis. The contents of our website and social media
postings, or any other website that may be accessed from our
website or social media postings, shall not be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended.
Absci Forward-Looking
Statements
Certain statements in this press release that
are not historical facts are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements containing the words “will,” “may,” “pursues,”
“anticipates,” “plans,” “believes,” “aims,” “potential,”
“forecast,” “estimates,” “extends,” “expects,” and “intends,” or
similar expressions. We intend these forward-looking statements,
including statements regarding technology development efforts and
the application of those efforts, including acceleration of drug
development timelines, reducing the time and costs related to drug
development, advancements in drug design, discovery and development
activities, the success of our partnership with Almirall and the
ability for the partnership to generate scientific and technical
insights for using AI drug creation to treat chronic inflammatory
diseases and to accelerate the development of treatments for
chronic and debilitating dermatological diseases, and the
anticipated payments to us under the collaboration, to be covered
by the safe harbor provisions for forward-looking statements
contained in Section 27A of the Securities Act and Section 21E of
the Securities Exchange Act, and we make this statement for
purposes of complying with those safe harbor provisions. These
forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies, and prospects, which
are based on the information currently available to us and on
assumptions we have made. We can give no assurance that the plans,
intentions, expectations, or strategies will be attained or
achieved, and furthermore, actual results may differ materially
from those described in the forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control, including, without limitation, risks and uncertainties
relating to our ability to effectively collaborate on research,
drug discovery and development activities with our partners or
potential partners; our existing and potential partners’ ability
and willingness to pursue the development and commercialization of
programs or product candidates under the terms of our partnership
agreements; and overall market conditions and regulatory
developments that may affect our and our partners’ activities under
these agreements, along with those risks set forth in our most
recent periodic report filed with the U.S. Securities and Exchange
Commission, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the U.S. Securities and Exchange Commission. Except as
required by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Almirall’s legal warning
This document includes only summary information
and is not intended to be exhaustive. The facts, figures and
opinions contained in this document, in addition to the historical
ones, are "forward-looking statements". These statements are based
on the information currently available and the best estimates and
assumptions that the company considers reasonable. These statements
involve risks and uncertainties beyond the control of the company.
Therefore, actual results may differ materially from those declared
by such forward-looking statements. The company expressly waives
any obligation to revise or update any forward-looking statements,
goals or estimates contained in this document to reflect any
changes in the assumptions, events or circumstances on which such
forward-looking statements are based, unless required by the
applicable law.
Media contact Almirall |
Investors’ Relations contact |
Tinkle |
Almirall |
Laura Blázquez |
Pablo Divasson del Fraile |
lblazquez@tinkle.es |
pablo.divasson@almirall.com |
Phone: (+34) 600 430 581 |
Phone: (+34) 93 291 30 87 |
Corporate Communications
contact
Almirall
Mar Ramírez
mar.ramírez@almirall.com
Phone: (+34) 659 614
173
Absci Investor Contact |
Absci Media Contact |
|
|
Alex Khan |
press@absci.com |
VP, Finance & Investor Relations |
|
investors@absci.com |
|
Alliance Mining (TSXV:ALM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Alliance Mining (TSXV:ALM)
Historical Stock Chart
From Aug 2023 to Aug 2024